GC Therapeutics
PrivateLast Round
Series A
Sep 19, 2024
Total Funding Raised
$75M
Company Overview
GC Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in September 2024.
GC Therapeutics is a biotechnology company that specializes in programming patient-derived stem cells into various cell types using an innovative platform that combines synthetic biology and artificial intelligence to create advanced cell therapies with enhanced manufacturing efficiency and quality.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GC Therapeutics Comparables
Compare GC Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Syntax Bio | 88% | |
| Trailhead Biosystems Inc. | 82% | |
| Mogrify | 82% |
For institutional investors. Book with your work email.
GC Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GC Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A, Seed |
| Cormorant Asset Management | Series A |
| Gaingels | Series A |
| Global Brain Corporation | Series A |
| Medical Excellence Capital | Series A |
| Pear VC | Series A |
| Mubadala Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 9, 2026
Kate Haviland appointed as new board chair.
- Apr 1, 2025
Proprietary TFome™ platform developed in Professor George Church's lab.
For institutional investors. Book with your work email.
GC Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GC Therapeutics's valuation, stock price, and market status.
Is GC Therapeutics a public or private company?
GC Therapeutics is a private company.
What is the current stock price of GC Therapeutics?
GC Therapeutics is a private company, so its shares have no public market price. Caplight tracks GC Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GC Therapeutics worth (valuation)?
Valuation information for GC Therapeutics is not publicly available.
Can I buy GC Therapeutics stock?
GC Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GC Therapeutics's last funding round?
GC Therapeutics's most recent funding round was Series A on September 19, 2024.
Who are the main investors in GC Therapeutics?
Key investors in GC Therapeutics include Andreessen Horowitz, Cormorant Asset Management, Cormorant Asset Management.
Will GC Therapeutics IPO soon?
No public IPO plans have been announced for GC Therapeutics.
How can I track GC Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in GC Therapeutics's shares on secondary markets.